Analytical Biological Services (ABS Bio), a biospecimen sourcing, cell culture, and biorepository solutions provider backed by 3 Boomerang Capital, has acquired Cureline, Inc., a specimen procurement and histology services firm serving pharmaceutical and life sciences customers. The deal, announced January 6, 2026, is ABS Bio’s first add-on acquisition since 3 Boomerang’s initial investment in June 2024.
Founded in 2003 by Olga Potapova, PhD, Cureline is headquartered in South San Francisco and provides biospecimen procurement and analysis, histology, and digital pathology services from a Bay Area facility. ABS Bio said the acquisition broadens access to biospecimens and adds depth across specimen procurement and histology, as biopharma customers contend with more complex sourcing needs and therapeutic programs.
ABS Bio, founded in 1990, provides custom biological products and services including cell culture services, cell-line engineering, human biospecimens, tissue and cell preparation and analysis, and sample storage and logistics. The combined platform is expected to increase scale, expand geographic reach, and enhance end-to-end execution from initial request through delivery.
KEY QUOTES:
“Cureline has built an exceptional reputation in the biospecimens and research space, and we are excited to welcome their team to ABS. This acquisition meaningfully expands our capacity and expertise while enabling us to remain focused on what matters most for scientific breakthroughs: broader access to biospecimens, flawless execution, and outstanding customer experience from initial request to delivery.”
Ehab Alramahy, CEO, ABS Bio
“Cureline was built on scientific excellence, global collaboration, and commitment to partnerships in research and drug discovery. ABS and Cureline are highly complementary in customer focus, regional scope of biospecimen collections, and service capabilities. By joining forces, our teams can offer a broader platform supported by a wider biospecimen network, deeper services expertise, and expanded biorepository capabilities.”
Olga Potapova, PhD, Founder, Cureline
